Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

• Published in: Aging clinical and experimental research 2021-08, Vol.33 (8), p.2355-2359
• Main Authors: Calafat, Margalida, González-Muñoza, Carlos, Fortuny, Marta, Roig, Cristina, Calm, Anna, Mombiela, Antonio, Cañete, Fiorella, Bertoletti, Federico, González-González, Laura, Teller-Martín, Marta, Gordillo, Jordi, Mañosa, Míriam, Garcia-Planella, Esther, Domènech, Eugeni
• Format: Article
• Language: English
• Subjects: Aged; Coronaviruses; COVID-19; Geriatrics/Gerontology; Humans; Immunosuppressive agents; Immunosuppressive Agents - adverse effects; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - epidemiology; Medicine; Medicine & Public Health; Risk Factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Short Communication
• ISSN: 1720-8319; 1594-0667; 1720-8319
• DOI: 10.1007/s40520-021-01917-9

Background Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. Aim To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. Methods IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. Results Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P  = 0.933) and 7 (22%) patients died. Conclusions Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.